The cardiac myosin inhibitor mavacamten substantially improved health status in patients with symptomatic obstructive hypertrophic cardiomyopathy, with benefits observed early after treatment, according to new data from EXPLORER-HCM.

Presenting new health status data from the trial at the American College of Cardiology Scientific Session, John A. Spertus, MD, MPH, with Saint Luke’s Mid America Heart Institute and the Lauer/Missouri Endowed Chair and professor at UMKC, said mean Kansas City Cardiomyopathy Questionnaire overall summary score differences favoring mavacamten (MyoKadria) were amongst the largest he has observed for any medication, eclipsed only by structural heart interventions.

“There is a very impressive improvement in the symptoms, function and quality of life of [mavacamten]-treated patients and it is really impressive that, when on the medicine, patients get the benefit; when they come off the medicine, benefit goes away,” Spertus told Healio. “It supports a direct cause-and-effect relationship between treatment and improved health status.”

Read the full Healio article: Marked health status improvement with mavacamten in obstructive hypertrophic cardiomyopathy